Immunotherapy, Adoptive

"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)

Descriptor ID	D016219
MeSH Number(s)	E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
Concept/Terms	Immunotherapy, Adoptive Immunotherapy, Adoptive Immunotherapy, Adoptive Cellular Adoptive Immunotherapy Adoptive Immunotherapies Immunotherapies, Adoptive Cellular Immunotherapy, Adoptive Adoptive Cellular Immunotherapies Cellular Immunotherapies, Adoptive Immunotherapies, Adoptive Cellular Adoptive Cellular Immunotherapy

Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Biological Therapy [E02.095]
Immunomodulation [E02.095.465]
Immunotherapy [E02.095.465.425]
Immunization [E02.095.465.425.400]
Immunization, Passive [E02.095.465.425.400.330]
Adoptive Transfer [E02.095.465.425.400.330.050]
Immunotherapy, Adoptive [E02.095.465.425.400.330.050.400]
Investigative Techniques [E05]
Immunologic Techniques [E05.478]
Immunization [E05.478.550]
Immunization, Passive [E05.478.550.520]
Adoptive Transfer [E05.478.550.520.050]
Immunotherapy, Adoptive [E05.478.550.520.050.400]

Below are MeSH descriptors whose meaning is related to "Immunotherapy, Adoptive".

Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.

Bar chart showing 13 publications over 12 distinct years, with a maximum of 2 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
2000	1	0	1
2009	0	1	1
2011	1	0	1
2012	0	1	1
2013	1	0	1
2015	1	0	1
2017	1	0	1
2019	1	0	1
2020	2	0	2
2022	0	1	1
2024	1	0	1

Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.

Short L, Holt RA, Cullis PR, Evgin L. Direct in vivo CAR T cell engineering. Trends Pharmacol Sci. 2024 May; 45(5):406-418.

View in: PubMed
Kekre N, Hay KA, Webb JR, Mallick R, Balasundaram M, Sigrist MK, Clement AM, Nielsen JS, Quizi J, Yung E, Brown SD, Dreolini L, Waller DD, Smazynski J, Gierc NS, Loveless BC, Clark K, Dyer T, Hogg R, McCormick L, Gignac M, Bell S, Chapman DM, Bond D, Yong S, Fung R, Lockyer HM, Hodgson V, Murphy C, Subramanian A, Wiebe E, Yoganathan P, Medynski L, Vaillan DC, Black A, McDiarmid S, Kennah M, Hamelin L, Song K, Narayanan S, Rodrigo JA, Dupont S, Hawrysh T, Presseau J, Thavorn K, Lalu MM, Fergusson DA, Bell JC, Atkins H, Nelson BH, Holt RA. CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. Front Immunol. 2022; 13:1074740.

View in: PubMed
Goruganthu MUL, Shanker A, Dikov MM, Carbone DP. Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings. Front Immunol. 2020; 11:1958.

View in: PubMed
Khalife R, Montroy J, Grigor EJM, Fergusson DA, Atkins H, Seftel M, Presseau J, Thavorn K, Holt RA, Hay K, Lalu MM, Kekre N. Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study. Br J Haematol. 2020 10; 191(1):e14-e19.

View in: PubMed
Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA, Lalu MM. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2019 04; 33(2):98-110.

View in: PubMed
Pellom ST, Singhal A, Shanker A. Prospects of combining adoptive cell immunotherapy with bortezomib. Immunotherapy. 2017 03; 9(4):305-308.

View in: PubMed
Shanker A, Pellom ST, Dudimah DF, Thounaojam MC, de Kluyver RL, Brooks AD, Yagita H, McVicar DW, Murphy WJ, Longo DL, Sayers TJ. Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Res. 2015 Dec 15; 75(24):5260-72.

View in: PubMed
Trivedi NH, Guentzel MN, Rodriguez AR, Yu JJ, Forsthuber TG, Arulanandam BP. Mast cells: multitalented facilitators of protection against bacterial pathogens. Expert Rev Clin Immunol. 2013 Feb; 9(2):129-38.

View in: PubMed
Grupp SA, Prak EL, Boyer J, McDonald KR, Shusterman S, Thompson E, Callahan C, Jawad AF, Levine BL, June CH, Sullivan KE. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin Cancer Res. 2012 12 15; 18(24):6732-41.

View in: PubMed
Malhotra A, Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy. 2011 Oct; 3(10):1143-66.

View in: PubMed

People

Explore

Similar Concepts

Top Journals